http://www.cnr.it/ontology/cnr/individuo/prodotto/ID299336

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia (Articolo in rivista)

Type

Label

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia (Articolo in rivista) (literal)

Anno

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

Alternative label

Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Sparta A, McCubrey JA, Martelli AM. (2013)
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia
in Expert opinion on therapeutic targets
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Sparta A, McCubrey JA, Martelli AM. (literal)

Pagina inizio

Pagina fine

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

http://www.scopus.com/inward/record.url?eid=2-s2.0-84880354180&partnerID=q2rCbXpz (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

Note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

Institute of Molecular Genetics, National Research Council-Rizzoli Orthopedic Institute, Bologna, Italy; Muscoloskeletal Cell Biology Laboratory, IOR, Bologna, Italy; DIBINEM-University of Bologna, 48, via Irnerio, Bologna, BO 40125, Italy; Brody School of Medicine, East Carolina University Greenville, Department of Microbiology and Immunology, Greenville, NC 27858, United States (literal)

Titolo

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia (literal)

Abstract

Introduction: Despite continuous advances in our knowledge of the biology of acute myelogenous leukemia (AML), the prognosis of AML patients treated with standard chemotherapy is still poor, especially in the elderly. Therefore, there is a need for novel targeted and less toxic therapies, particularly for patients who develop resistance to traditional chemotherapeutic drugs. Constitutively active phosphatidylinositol 3-kinase (PI3K) signaling characterizes many types of tumors, including AML, where it negatively influences response to therapeutic treatments. Areas covered: The literature data showed that small inhibitor molecules targeting PI3K signaling induced cell cycle arrest, apoptosis and decreased drug-resistance in AML cells. PI3K inhibitors were also capable of targeting leukemic initiating cells (LICs), the most relevant target for leukemia eradication, whereas they tended to spare healthy hematopoietic stem cells. Expert opinion: Data emerging from pre-clinical settings suggest that the PI3K pathway is critically involved in regulating proliferation, survival and drug-resistance of AML cells. Therefore, we propose that novel drugs targeting this signaling pathway may offer a novel and less toxic treatment option for AML patients, most likely in combination with a lower dosage of traditional chemotherapeutic agents or other innovative therapeutic agents. © Informa UK, Ltd. (literal)

Prodotto di